Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Probiotics With High Expression of DL-peptidase (LR607) Can Enhance the Efficacy of Chemoradiotherapy in Resectable Stage IIB-IIIB Non-small Cell Lung Cancer: a Single-arm, Open-label, Multicenter, Phase II Clinical Trial

NCT07534033 is registered in ClinicalTrials.gov with Zhujiang Hospital as lead sponsor.

NCT NCT07534033
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07534033 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Probiotics With High Expression of DL-peptidase (LR607) Can Enhance the Efficacy of Chemoradiotherapy in Resectable Stage IIB-IIIB Non-small Cell Lung Cancer: a Single-arm, Open-label, Multicenter, Phase II Clinical Trial
Lead sponsor
Zhujiang Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
December 6, 2025
Completion date
December 23, 2027
Enrollment
46 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

a multidisciplinary team assessment determined that the patient was a suitable candidate for radical surgical resection, ajcc is classified as ib-iiic, nsclc diagnosed by histology or cytology, overall lung function is adequate for the planned lung resection